Following publication of research findings in the journal Science Translational Medicine, Patrik Brundin, MD, PhD, director of Van Andel Research Institute’s Center for Neurodegenerative Science, and chairman of The Cure Parkinson’s Trust’s Linked Clinical Trials Committee, discusses MSDC-0160, a new investigational drug originally developed for type 2 diabetes that is being readied for human clinical trials in search of the world’s first treatment to impede the progression of Parkinson’s disease.

Credit: Video courtesy of the Patrik Brundin Laboratory, Van Andel Research Institute.

Read more...

Alzheimer's Disease Facts and Figures 2016

2016 Alzheimer’s Disease Facts and Figures is a statistical resource for U.S. data related to Alzheimer’s disease, the most common type of dementia, as well as other dementias. Alzheimer’s disease is a degenerative brain disease and the most common cause of dementia. Dementia is characterized by a decline in memory, language, problem-solving and other cognitive skills that affects a person’s ability to perform everyday activities. This decline occurs because nerve cells (neurons) in parts of the brain involved in cognitive function have been damaged or destroyed. In Alzheimer’s disease, the damage and destruction of neurons eventually affect other parts of the brain, including those that enable a person to carry out basic bodily functions such as walking and swallowing. People in the final stages of the disease are bed-bound and require around-the-clock care. Alzheimer’s disease is ultimately fatal. (Alzheimer’s Association. 2016 Alzheimer’s Disease Facts and Figures. Alzheimer’s & Dementia 2016;12(4).)

Read more...

Diabetes Can and Should be Prevented

DiabetesInfographic-Screenshot-forWeb$245 billion is spent annually to treat type 2 diabetes in the U.S. Globally, nearly 50 percent of those diagnosed with diabetes live in just 3 countries (China, India, U.S.). Yet, diabetes can and should be prevented.

Read more...

New Approach to Treating "Type 3 Diabetes"

MSDC_alzheimers_WebICONAlzheimer’s disease has been characterized as “type 3 diabetes.” Insulin sensitizers may play a role in treating Alzheimer’s disease and MSDC has developed a new insulin sensitizer that may prevent cognitive decline in people with Alzheimer’s-related dementia.

Read more...

mTOT Modulators

Data presented to date suggest that the mTOT protein complex functions as a molecular "sensor switch" connecting mitochondrial metabolism to important cellular activities perturbed in age-related metabolic diseases such as type 2 diabetes, including insulin sensitivity. MSDC's novel pharmaceutical agents selectively bind and modulate proteins in the mTOT complex, effecting pyruvate utilization and resulting in improved insulin action, lipid oxidation, preservation of beta cell function, and generation of brown fat.

Read more...

The Science of Diabetes

Type 2 diabetes is a metabolic disorder affecting the ways in which the body uses various nutrients for growth and energy. The root cause of this disorder is insulin resistance, which is a result of the body's inability to efficiently and effectively convert glucose - a simple sugar made from the food you eat - to energy. Insulin, a hormone produced by the beta cells in the pancreas, aids in the transfer of glucose into the bloodstream, where it is used or metabolized by cells for growth and energy. Diabetes results when changes in metabolism alter both the ability of insulin to work on its target tissues and the ability of the beta cells to make and secrete insulin.

Read more...

New Drug Target Identified for Treatment of Type 2 Diabetes

A mitochondrial protein complex has been identified by researchers at Metabolic Solutions Development Company (MSDC) through which anti-diabetic drugs exert their insulin sensitizing effects when used to treat patients diagnosed with type 2 diabetes. The mitochondrial protein complex is being referred to as the mitochondrial Target of Thiazolidinediones (TZDs), or mTOT™.

Read more...

First in Class mTOT Modulator Meets Phase 2b Study Endpoints

In a recently completed Phase 2b study, MSDC-0160, a novel once-a-day oral insulin sensitizer and a prototype first in a new class of therapeutic agents called mTOT Modulators™, which are being developed by researchers at Metabolic Solutions Development Company (MSDC), met the primary endpoint of significantly reducing fasting plasma glucose (FPG) in patients diagnosed with type 2 diabetes, and significantly reduced hemoglobin A1c (HbA1c).

Read more...

New Research Suggests Novel Insulin Sensitizer Works Through a New Mechanism to Treat Root Cause of Type 2 Diabetes

Washington University School of Medicine researchers show MSDC compound has anti-diabetic efficacy without side effects profile of current drugs to treat insulin resistance

A study published online in the Journal of Biological Chemistry, titled “Insulin Resistance and Metabolic Derangements in Obese Mice are Ameliorated by a Novel Peroxisome Proliferator-Activated Receptor-sparing Thiazolidinedione”, showed a new drug to treat diabetes being developed by Metabolic Solutions Development Company (MSDC), MSDC-0602, improved insulin resistance and inflammation in obese mice. These findings suggest that MSDC-0602, a novel anti-diabetic drug which is in Phase 2 clinical trials, may constitute the first in a class of next generation insulin sensitizers that appear to work through a new biochemical mechanism to treat insulin resistance and type 2 diabetes.

Read more...